With Myriad Genetics' announcement this week that it will acquire Crescendo Bioscience for $270 million in cash, clinical proteomics has scored what is perhaps its most significant endorsement to date.

The field has notched a number of advances in recent years, including product launches, US Food and Drug Administration clearances, and the increasing adoption of mass spec as a clinical tool. In terms of actual profits, however, proteomic diagnostics have, generally speaking, underwhelmed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.